At Indel Bioinnovations, we develop next-generation gene therapies to restore the body’s natural defenses against cancer. Our lead program targets triple-negative breast cancer by reactivating key tumor suppressor pathways. We’re focused on creating treatments that are broadly applicable, scalable, and built for the real-world challenges of modern oncology.
Feel free to sign up to receive regular updates on our scientific and business accomplishments!
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.